{"id":3708,"date":"2026-11-10T03:59:47","date_gmt":"2026-11-09T19:59:47","guid":{"rendered":"http:\/\/www.center-intex.com\/blog\/?p=3708"},"modified":"2026-11-10T03:59:47","modified_gmt":"2026-11-09T19:59:47","slug":"are-there-any-international-standards-for-pharmaceutical-intermediates-4310-39deff","status":"publish","type":"post","link":"http:\/\/www.center-intex.com\/blog\/2026\/11\/10\/are-there-any-international-standards-for-pharmaceutical-intermediates-4310-39deff\/","title":{"rendered":"Are there any international standards for pharmaceutical intermediates?"},"content":{"rendered":"<p>Hey everyone, so here\u2019s the thing: I\u2019m a pharmaceutical intermediates supplier, and more times than I can count, I get this question from both new clients and folks I\u2019ve worked with for years\u2014\u201cAre there actual international standards for pharmaceutical intermediates?\u201d Let me cut to the chase: it\u2019s not a straight yes or no, but it\u2019s way less confusing than you\u2019d think once you dig past the jargon. First off, let\u2019s make sure we\u2019re all on the same page: pharmaceutical intermediates (or just \u201cpharma intermediates\u201d for short) are the mid-stage chemicals you make along the way to a final drug. You don\u2019t dose people with them\u2014they\u2019re the building blocks, like the frame of a house before you add the drywall and paint. So why do standards even matter here? If your intermediate is dirty, or made with sketchy processes, it can mess up the final drug\u2019s safety, efficacy, or even get it rejected by regulators. That\u2019s the big red line for everyone, from small biotechs to big pharma. <a href=\"https:\/\/www.vistar-chem.com\/life-science-chemicals\/pharmaceutical-intermediates\/\">Pharmaceutical Intermediates<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.vistar-chem.com\/uploads\/48846\/small\/cas-4378-70-5-2-amino-ethanesulfonamide-nsc7a341.jpg\"><\/p>\n<p>Now, let\u2019s talk international standards. A lot of people mix up \u201cguidelines\u201d with \u201cstandards,\u201d and I get why\u2014they sound interchangeable. But for pharma intermediates, there\u2019s no single global rulebook, mostly because different regions have their own regulators, and they\u2019ve aligned a lot on key stuff through groups that work across borders. The main player here is ICH\u2014International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Yeah, I used the acronym, that\u2019s how we say it in the industry. ICH puts out guidelines that are adopted by regulators in the EU, US, Japan, Canada, and a bunch of other countries. One of their big ones is Q7, right? ICH Q7 is specifically for good manufacturing practices (GMP) for active pharmaceutical ingredients (APIs), but wait\u2014key point here: it also covers intermediates that are used to make APIs. So if you\u2019re an intermediate supplier, even though you\u2019re not making the final API, ICH Q7 is the baseline a lot of us follow. That\u2019s not a mandatory standard on its own, but if you don\u2019t align with it, you\u2019ll struggle to sell to any big pharma or get your intermediates into a drug that crosses borders.<\/p>\n<p>Then there\u2019s other stuff, like ISO standards. ISO is the International Organization for Standardization, and they have a few that apply here. ISO 9001 is general quality management, which every serious intermediate supplier should have, no question. But there\u2019s also ISO 13485, wait\u2014no, that\u2019s more for medical devices. For intermediates, ISO 22000? No, that\u2019s food safety. Wait, actually ISO has a specific series for chemicals, ISO 14001 for environmental management, which is big because pharma intermediates manufacturing uses a lot of chemicals and has waste to handle. Oh, and there\u2019s ISO\/IEC 17025 for testing labs\u2014we use that for our in-house quality control, so our test results are credible no matter where a client is from. But again, these are management system standards, not strict \u201cthis chemical must be 99.5% pure\u201d rules.<\/p>\n<p>Wait, let\u2019s get to the nitty-gritty that matters to suppliers like me. Let\u2019s say a client asks for an intermediate that\u2019s going into a generic on the US market. They\u2019ll expect us to follow ICH Q7, because the FDA (US regulator) references ICH guidelines all the time. If it\u2019s for a drug in the EU, the EMA (European Medicines Agency) does the same. But what about smaller markets? Like, a client in Brazil or India? A lot of them will accept ICH-aligned docs too, because it\u2019s easier than building their own standards from scratch. But here\u2019s the catch: ICH Q7 is vague on a lot of intermediate-specific stuff. For example, it says you need to control impurities, but it doesn\u2019t tell you exactly what limits to set for every possible impurity. That\u2019s where we, as suppliers, have to fill in the gaps by either following industry consensus (like from groups like the Pharmaceutical Quality Group, or PQG) or working directly with our clients to match their specific requirements. And honestly, that\u2019s where the good suppliers separate themselves from the ones cutting corners. If you just follow the minimum ICH rules without validating your processes, you\u2019re going to get rejected sooner or later.<\/p>\n<p>I\u2019ve seen this first-hand. A few years back, I worked with a small biotech that was testing a new drug for rare diseases. They had a super tight timeline, so they tried a cut-rate intermediate supplier who said they met \u201cinternational standards.\u201d When we did our independent testing, we found that one impurity was just under the limit that the ICH Q7 guideline recommends for that type of intermediate\u2014turns out the cheap supplier didn\u2019t have the right testing equipment to catch it. We ended up switching to a more rigorous process, and the biotech\u2019s drug went on to get FDA approval. That\u2019s not just a money thing; that\u2019s a patient thing. If that impurity had made it into the final drug, who knows what could\u2019ve happened. So even if there\u2019s no single international \u201ccertified\u201d standard for intermediates, following the aligned guidelines from ICH, plus having your own quality systems that stack up, is non-negotiable.<\/p>\n<p>Wait, let\u2019s address the elephant in the room: are there any actual mandatory international standards? No, not for intermediates specifically. Every country has its own set of rules, but they\u2019re all converging on the ICH stuff. For example, the FDA has its own GMP regulations (21 CFR Part 211) which is almost identical to ICH Q7 when it comes to intermediates. The EMA has GMP guidelines that also line up. So it\u2019s less \u201cinternational standard\u201d and more \u201cglobal alignment of standards\u201d thanks to ICH. That\u2019s a key distinction. A lot of new people in the industry get tripped up here\u2014they think there\u2019s one stamp you can put on your product, like a CE mark, but it doesn\u2019t work that way for intermediates. You have to show documentation that you\u2019re following the relevant guidelines, and that your quality processes are consistent.<\/p>\n<p>Another thing: impurity profiling. That\u2019s a big part of intermediate standards, and it\u2019s where ISO and ICH overlap a lot. ICH has guidelines on what qualifies as a \u201cthreshold\u201d for impurities\u2014like, any impurity above 0.1% has to be identified and tested for safety. That\u2019s a rule we follow every single day. If we make an intermediate with a new process, we have to do a full impurity profile, send it to our client, and usually get it approved by their regulatory team before we can ship. No cutting corners here. And that\u2019s not just a recommendation\u2014it\u2019s expected by every major regulator, so it\u2019s basically the closest thing to an international standard we have for intermediates.<\/p>\n<p>Now, let\u2019s talk about what this means for us as suppliers. We don\u2019t just check a box and call it a day. We have a full quality team that works with regulatory affairs to make sure every batch we make complies with ICH Q7, our ISO 9001 certification, and any specific requirements our client has. For example, if a client is making a drug for a pediatric indication, they might ask us to lower the impurity thresholds beyond what ICH recommends, because kids are more sensitive to chemicals. We adjust our processes to meet that, no extra charge, because that\u2019s just part of the job.<\/p>\n<p>I should also mention that there are some regional standards that are worth noting, even if they\u2019re not global. For example, Japan\u2019s JP (Japanese Pharmacopoeia) has standards for many intermediates, and they line up almost exactly with ICH, so again, that\u2019s alignment, not a new standard. The US Pharmacopoeia (USP) has monographs for some intermediates, which are specific specifications for purity, identity, and testing. A lot of suppliers, including us, follow USP monographs where they exist, because they\u2019re widely recognized. So even if there\u2019s no global standard, these pharmacopeias act as a common reference point across countries.<\/p>\n<p>Wait, let\u2019s make sure I\u2019m not downplaying the gaps. There are still a lot of intermediates that don\u2019t have a USP monograph, or specific ICH guidelines for their use case. That\u2019s where communication between supplier and client is key. If a client tells us their intermediate is going into a generic drug approved by the EMA, we know exactly which guidelines to follow. If it\u2019s a research chemical for a university lab testing a new compound, we can relax a bit, but still keep quality high. Because even research intermediates can turn into commercial drugs one day, so we never skip important testing.<\/p>\n<p>I\u2019ve had so many clients say to me, \u201cI wish there was a single international standard so I didn\u2019t have to rewrite my documentation every time I switch suppliers.\u201d I get that\u2014it would make life easier. But the way things are now, the alignment across ICH, USP, and regional regulators is the best we\u2019ve got, and it\u2019s way better than it was 20 years ago. When I first got into this industry, every country had totally different rules, and it was a nightmare to ship intermediates between Europe and the US. Now, with ICH, it\u2019s way more straightforward.<\/p>\n<p>Let me also touch on enforcement. It\u2019s one thing to have guidelines, it\u2019s another to actually follow them. As a supplier, we get audited all the time\u2014by clients, by regulatory bodies, by third-party auditors. If we skip a step in our process, or if our testing is shoddy, we get flagged, and we could lose clients, or even face regulatory action. That\u2019s a big motivator. It\u2019s not just about checking boxes; it\u2019s about keeping our clients\u2019 drugs safe, and keeping our own business trustworthy.<\/p>\n<p>So to circle back to the original question: are there any international standards for pharmaceutical intermediates? The answer is, not a single, universal one, but there\u2019s a global framework of aligned guidelines, pharmacopeial references, and management system standards that act as the de facto rules. For suppliers like me, that means we have to stay up to date on ICH updates, maintain our ISO certifications, work closely with clients, and never cut corners on quality. Because at the end of the day, our intermediates are the foundation of drugs that help people, whether that\u2019s a cancer treatment, a diabetes drug, or something for a rare disease. If we mess up the foundation, the whole thing falls apart.<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.vistar-chem.com\/uploads\/48846\/small\/cas-84434-05-9-9-oxo-9h-thioxanthene-2-yloxy86eac.jpg\"><\/p>\n<p>Now, if you\u2019re a pharma professional looking for a reliable intermediate supplier, someone who gets how important compliance and quality are, and who works with you to meet your specific needs\u2014reach out. We\u2019re here to walk you through our processes, share our quality docs, and make sure you get exactly what you need, every single time. No jargon, no runaround, just straight talk and solid chemicals.<\/p>\n<p><a href=\"https:\/\/www.vistar-chem.com\/material-chemicals\/chemical-reagents\/\">Chemical Reagents<\/a> References:<\/p>\n<ol>\n<li>International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.<\/li>\n<li>International Organization for Standardization (ISO). ISO 9001: Quality Management Systems Requirements.<\/li>\n<li>U.S. Food and Drug Administration (FDA). 21 CFR Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals.<\/li>\n<li>European Medicines Agency (EMA). GMP Guidelines for Medicinal Products for Human Use.<\/li>\n<li>United States Pharmacopeia (USP). General Chapter &lt;1042&gt;: Pharmaceutical Compounding \u2013 Nonsterile Preparations.<\/li>\n<\/ol>\n<hr>\n<p><a href=\"https:\/\/www.vistar-chem.com\/\">Henan Vistar Biomedical Co., Ltd.<\/a><br \/>As one of the most professional pharmaceutical intermediates manufacturers in China, we have world-leading production equipment and strong manufacturing capabilities. Please feel free to buy bulk premium pharmaceutical intermediates at competitive price from our factory.<br \/>Address: Zhengzhou Linkong Yunchuang Industrial Park, Aviation Port District, Zhengzhou, Henan, China<br \/>E-mail: sale08@alfachem.cn<br \/>WebSite: <a href=\"https:\/\/www.vistar-chem.com\/\">https:\/\/www.vistar-chem.com\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hey everyone, so here\u2019s the thing: I\u2019m a pharmaceutical intermediates supplier, and more times than I &hellip; <a title=\"Are there any international standards for pharmaceutical intermediates?\" class=\"hm-read-more\" href=\"http:\/\/www.center-intex.com\/blog\/2026\/11\/10\/are-there-any-international-standards-for-pharmaceutical-intermediates-4310-39deff\/\"><span class=\"screen-reader-text\">Are there any international standards for pharmaceutical intermediates?<\/span>Read more<\/a><\/p>\n","protected":false},"author":240,"featured_media":3708,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[3671],"class_list":["post-3708","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-industry","tag-pharmaceutical-intermediates-44a3-3a140c"],"_links":{"self":[{"href":"http:\/\/www.center-intex.com\/blog\/wp-json\/wp\/v2\/posts\/3708","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.center-intex.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.center-intex.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.center-intex.com\/blog\/wp-json\/wp\/v2\/users\/240"}],"replies":[{"embeddable":true,"href":"http:\/\/www.center-intex.com\/blog\/wp-json\/wp\/v2\/comments?post=3708"}],"version-history":[{"count":0,"href":"http:\/\/www.center-intex.com\/blog\/wp-json\/wp\/v2\/posts\/3708\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.center-intex.com\/blog\/wp-json\/wp\/v2\/posts\/3708"}],"wp:attachment":[{"href":"http:\/\/www.center-intex.com\/blog\/wp-json\/wp\/v2\/media?parent=3708"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.center-intex.com\/blog\/wp-json\/wp\/v2\/categories?post=3708"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.center-intex.com\/blog\/wp-json\/wp\/v2\/tags?post=3708"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}